Hiromi Yoshiuchi
Japan Tobacco (Japan)(JP)
Publications by Year
Research Areas
Cancer, Hypoxia, and Metabolism, Erythropoietin and Anemia Treatment, Peptidase Inhibition and Analysis, Chemical Synthesis and Analysis, Parkinson's Disease Mechanisms and Treatments
Most-Cited Works
- → Discovery of JTZ-951: A HIF Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia(2017)51 cited
- → Discovery of (1S,2R,3R)-2,3-Dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: Novel and Highly Selective Aggrecanase Inhibitors(2011)49 cited
- → JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor(2019)43 cited
- → A Novel TNF-α Converting Enzyme (TACE) Selective Inhibitor JTP-96193 Prevents Insulin Resistance in KK-A<sup>y</sup> Type 2 Diabetic Mice and Diabetic Peripheral Neuropathy in Type 1 Diabetic Mice(2019)22 cited
- → Synthesis and SAR of 2-phenyl-1-sulfonylaminocyclopropane carboxylates as ADAMTS-5 (Aggrecanase-2) inhibitors(2009)19 cited
- → Novel N-substituted 2-phenyl-1-sulfonylamino-cyclopropane carboxylates as selective ADAMTS-5 (Aggrecanase-2) inhibitors(2009)17 cited
- → JTZ-951 (enarodustat), a hypoxia-inducible factor prolyl hydroxylase inhibitor, improves iron utilization and anemia of inflammation: Comparative study against recombinant erythropoietin in rat(2021)5 cited
- → Unilateral Nephrectomized SHR/NDmcr-cp Rat Shows a Progressive Decline of Glomerular Filtration With Tubular Interstitial Lesions(2023)4 cited
- → Tapinarof, a Novel Topical Therapeutic Aryl Hydrocarbon Receptor Agonist, Suppresses Atopic Dermatitis-like Skin Inflammation in Mice(2024)2 cited
- → Pharmacological Properties of Tapinarof in Mice as a Novel Topical Agent for Plaque Psoriasis(2024)1 cited